menu
    • menu

    Company profile for MetaVia

    NEW Drugs in Dev: 3
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    MetaVia is a clinical-stage biotechnology company focused on transforming the treatment of cardiometabolic diseases. The company is developing DA-1726 for obesity and DA-1241 for Metabolic Dysfunction-Associated Steatohepatitis (MASH). DA-1726 is a novel dual oxyntomodulin (OXM) analog that acts as a glucagon-like peptide-1 receptor (GLP1R) and glucagon receptor (GCGR) agonist, designed for once-weekly injection.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    MetaViaUnited_States_of_America Flag
    Country
    Country
    U.S.A
    Address
    Address
    545 Concord Avenue, Suite 210, Cambridge, MA 02138
    Telephone
    Telephone
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://metaviatx.com/
    Linkedin
    Linkedin
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    MetaVia Doses First Patient in Higher-Dose Ph 1 Study of DA-1726
    MetaVia Doses First Patient in Higher-Dose Ph 1 Study of DA-1726

    10 Apr 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/metavia-doses-the-first-patient-in-higher-dose-phase-1-study-of-da-1726-its-glp-1-and-glucagon-dual-agonist-for-the-treatment-of-obesity-302738622.html

    PR NEWSWIRE
    10 Apr 2026
    Share Share
    Metavia Reveals 2025 Financials And Corporate Update
    Metavia Reveals 2025 Financials And Corporate Update

    26 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/metavia-reports-year-end-2025-financial-results-and-provides-corporate-update-302725141.html

    PR NEWSWIRE
    26 Mar 2026
    Share Share
    MetaVia Extends Vanoglipel Patent to 2035 Globally
    MetaVia Extends Vanoglipel Patent to 2035 Globally

    12 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/metavia-expands-global-patent-protection-for-vanoglipel-supporting-metabolic-and-liver-disease-therapy-through-2035-302712075.html

    PR NEWSWIRE
    12 Mar 2026
    Share Share
    MetaVia to Highlight Novel Obesity and Metabolic Therapies
    MetaVia to Highlight Novel Obesity and Metabolic Therapies

    04 Mar 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-life-sciences-virtual-investor-forum-302703568.html

    PR NEWSWIRE
    04 Mar 2026
    Share Share
    MetaVia Showcases Obesity Therapies at Growth Conference
    MetaVia Showcases Obesity Therapies at Growth Conference

    17 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/metavia-to-highlight-novel-obesity-and-metabolic-therapies-at-upcoming-emerging-growth-conference-302688425.html

    PR NEWSWIRE
    17 Feb 2026
    Share Share
    MetaVia Secures DA-1726 Obesity Therapy Patents Until 2041
    MetaVia Secures DA-1726 Obesity Therapy Patents Until 2041

    13 Feb 2026

    // PR NEWSWIRE

    https://www.prnewswire.com/news-releases/metavia-builds-comprehensive-global-patent-protection-for-da-1726-securing-exclusive-rights-to-novel-obesity-and-metabolic-therapy-through-2041-302687014.html

    PR NEWSWIRE
    13 Feb 2026
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search